Join us at ESMO 2025! Find out how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions.

We are excited to be back at ECP in 2025! Join us and explore more about our recent developments in Liquid Biopsy, CGP, Solid Tumors and more! 

#PrecisionMedicine #RealWorldData #Genomics #DataDrivenMedicine #Oncology

SOPHiA GENETICS™ thrilled to be back at ESHG 2025! Come meet our team to learn how SOPHiA GENETICS can help turn complex generic data into life-changing Insights! 

SOPHiA GENETICS™ thrilled Charité Mayo Conference 2025! Visit us to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions.  

Join us at the 14th International Symposium on Minimal Residual Cancer (ISMRC) in Nice, France, where experts gather to explore the latest advancements in liquid biopsy. Discover how SOPHiA GENETICS is transforming cancer care through innovative solutions at the forefront of precision oncology. Visit our booth to learn more and connect with our team—see you there! 

SOPHiA GENETICS™ is thrilled to return for Festival of Genomics! Visit us at booth #91 to learn more about the New Generation SOPHiA DDM™ Platform and Alamut™ Visual Plus. 

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy.

Boston, MA and Rolle, Switzerland, September 14, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from the addition of tremelimumab to durvalumab and chemotherapy.

The research is a retrospective, multimodal analysis of the POSEIDON Phase 3 clinical trial (NCT03164616). This trial originally demonstrated that the combination of tremelimumab, durvalumab, and chemotherapy significantly increases progression-free survival (PFS) and overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, which lead to approval of this regiment globally in 1L mNSCLC. The SOPHiA GENETICS study used cutting-edge multimodal machine learning models to analyze clinical, biological, genomic, and imaging data, pinpointing patient subgroups who are most likely to benefit from the combination treatment.

The research highlighted signatures identifying patients with non-squamous metastatic NSCLC who may derive higher OS benefit from the addition of tremelimumab to durvalumab plus chemotherapy in the first-line treatment setting. In particular, EGFR wild-type, FGFR3 wild-type, CDKN2A wild-type, KRAS mutation, and STK11 mutation comprised elements of a signature was identified as being associated with a higher OS benefit. These findings could have significant implications for the treatment of NSCLC, as it provides an exploration avenue towards a more tailored approach to patient care.

"Our collaboration with AstraZeneca represents a major step forward in personalized oncology. Non-small cell lung cancer remains one of the most challenging cancers to treat due to its complex biology and the late stage at which it is often diagnosed,” said Jurgi Camblong, Ph.D., Co-founder and CEO of SOPHiA GENETICS. “This study harnesses the power of multimodal data and advanced AI to identify which patients are most likely to benefit from specific therapies. By tailoring treatment strategies based on a patient's unique multimodal profile, we aim to improve outcomes and offer new hope to those battling this difficult disease."

The study will be presented as a poster by Ferdinandos Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center at ESMO 2024 hosted in Barcelona, Spain from September 13-17, 2024. His presentation showcases the operational feasibility and clinical impact of large-scale multimodal analyses in identifying heterogeneous treatment effects in oncology.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.

###

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact: 
Kelly Katapodis
media@sophiagenetics.com

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials.

Boston, MA and Rolle, Switzerland, September 12, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024. The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

The details of the presentations are as follows:

Title:  Analytical validation of an NGS panel-based ecDNA detection device for use as a clinical trial assay for the POTENTIATE clinical study of the novel CHK1 inhibitor, BBI-355
Poster Session: New Diagnostic Tools, Poster #1198
Date/Time: Sunday, September 15, 2024, 17h20 CEST
Presenting Author: Julien Pontis, Technical Product Manager and Lead Data Scientist, SOPHiA GENETICS

This poster presentation will focus on the analytical validation of a next-generation sequencing (NGS) panel-based extrachromosomal DNA (ecDNA) detection device. This innovative device has been developed as a clinical trial assay for Boundless Bio’s ongoing, first-in-human POTENTIATE Phase 1/2 clinical study of its lead ecDNA-directed therapy (ecDTx), BBI-355.

“ecDNA-enabled cancers have a unique biology, with a growing body of research showing these tumors rapidly evolve and typically fail to respond to targeted therapies, leading to worse patient prognoses, including poor time to progression and overall survival. We have developed and validated a proprietary algorithm to detect ecDNA from the outputs of NGS panels routinely used to detect alterations in patient tumors that can be used to select patients for clinical trials,” said Julien Pontis, Technical Product Manager and Lead Data Scientist at SOPHiA GENETICS.

Title: TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial
Poster Session: NSCLC, Metastatic, Poster #1325
Date/Time: Saturday, September 14, 2024, 12h00 CEST
Presenting Author: Ferdinandos Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center

This poster will feature the TRIDENT study, which leverages machine learning to develop multimodal signatures that can identify patients who would benefit most from the addition of tremelimumab to the durvalumab and chemotherapy regimen in the context of first-line treatment of stage IV non-small cell lung cancer. Dr. Ferdinandos Skoulidis from the University of Texas MD Anderson Cancer Center will present the findings, which are based on a retrospective multimodal analysis of the POSEIDON Phase 3 trial.

Abstracts for these posters are available on the conference website.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.

###

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact: 
Kelly Katapodis
media@sophiagenetics.com

The global collective intelligence network aims to accelerate precision oncology research and care.

Boston, US, and Rolle, Switzerland, September 12, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY. SOPHiA UNITY is the global consortium announced at ASCO by SOPHiA GENETICS that connects best-in-class healthcare institutions to fuel the next wave of innovation in oncology by making real-world data available for research.

SOPHiA UNITY, the pioneering initiative by SOPHiA GENETICS, harnesses multimodal data and analytics to drive innovation from a global network. The bar for innovation in oncology is increasing as indications become more fragmented, more complex and requiring larger datasets. No single institution can address this challenge alone. SOPHiA GENETICS launched SOPHiA UNITY to meet this challenge, harmonizing high-quality, diverse, multimodal data at scale, leveraging the collective intelligence of leading research institutions.

Exactis Innovation in Montreal, Quebec, Canada, an organization of hospital partners dedicated to improving cancer survivorship through real-world data, as well as Institut Paoli-Calmettes in Marseille, France, one of the largest cancer centers in France, will be joining SOPHiA UNITY. In addition, Gemelli Hospital in Rome, Italy, named the best hospital in Italy in 2024, has expressed interest in joining the collaborative.

These organizations accompany inaugural member Memorial Sloan Kettering Cancer Center, a top cancer treatment and research institution. The SOPHiA UNITY network includes three countries and over 100,000 committed patient profiles with multimodal data.

“By uniting a critical mass of data and expertise through SOPHiA UNITY, we are empowering a global network of top-tier institutions to leverage real-world data to tackle the complexities of cancer. This initiative provides a new opportunity to advance oncology research with one of the most robust sources of diverse data available in the market to drive breakthroughs and improve patient outcomes worldwide," said Jurgi Camblong, PhD, Co-founder and CEO of SOPHiA GENETICS. "Together, we have the power to change the world."

Members benefit from participating in innovative global projects funded by industry and have access to the SOPHiA GENETICS AI-driven technology that increases efficiency of data curation, structuring and harmonization efforts. Collaborations made possible by SOPHiA UNITY pave the way for continued advancement of oncology research and data-driven medicine.

Members of SOPHiA UNITY can use SOPHiA CarePath™ which provides large-scale data insights from various modalities—including imaging, genomics, and pathology, as well as clinical notes and a diverse array of patient profiles. Data are safely and anonymously collected, harmonized and curated using SOPHiA GENETICS’ advanced AI-based technology and proprietary algorithms, delivering meaningful, data-driven insights. 

For more information visit SOPHiAGENETICS.COM, or connect on LinkedIn.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact:
Kelly Katapodis
media@sophiagenetics.com

Boston, US, and Rolle, Switzerland, September 7, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care.

SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). This non-invasive testing allows for cancer genomic profiling and disease monitoring. It reveals critical insights in many cases where genomic testing of tumor tissue may not be feasible due to insufficient tissue material, low quality of the obtained tissue, or the invasiveness of the procedure. 

The ELBS primarily focuses on liquid biopsy testing for cancer, which aligns with the work that SOPHiA GENETICS has done to increase access to this sophisticated testing. SOPHiA GENETICS decentralized MSK-ACCESS®, the highly validated ctDNA assay developed by Memorial Sloan Kettering Cancer Center (MSK), so customers in Europe and worldwide have access to a best-in-class liquid biopsy solution.

“ELBS facilitates scientific exchange, clinical studies, and networking between leading experts, and we are thrilled to have SOPHiA GENETICS bring their global expertise and insights to our dynamic network of partners as we advance the field of liquid biopsy,” said Dr. Klaus Pantel, Founder and Chairman of the ELBS.

“We are impressed by the expansive community that the ELBS has created and are looking forward to collaborating with the ELBS to move this groundbreaking field forward to further widespread adoption and reimbursement for liquid biopsy testing,” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS.  “We believe that our participation will bring best-in-class technology and key learnings from our global community to complement and enhance the work of the ELBS moving forward.”

The ELBS network currently consists of more than 87 member institutions including academic institutions and university hospitals, as well as industry partners spread across biotech, device manufacturers, diagnostic companies, standard providers and pharmaceutical companies. Several members of the society, such as IUCT-Oncopole, work with SOPHiA GENETICS for liquid biopsy testing.

“We are pleased to welcome SOPHiA GENETICS to the European Liquid Biopsy Society. As the first laboratory in France and first European Liquid Biopsy member to adopt the MSK-ACCESS® powered with SOPHiA DDM™ application, we have experienced firsthand the technical expertise of the team at SOPHiA GENETICS combined with the analytical power of the SOPHiA DDM™ Platform to produce high-quality, meaningful insights for our teams. We are looking forward to continuing to further the field of liquid biopsy while serving our patients alongside the SOPHiA GENETICS team,” said a representative of the biology laboratory of medical oncology from IUCT-Oncopole in Toulouse.

###

About European Liquid Biopsy Society

The European Liquid Biopsy Society” Network was developed from the EU IMI “CANCER-ID” project (2015-2019) to further strengthen the field of Liquid Biopsy. The ELBS combines domestic and international orientation and promotes exchange between academic, industrial and clinical sectors as well as the health care system.

The network is further intended to promote the development of standardized guidelines and training in the field of “Liquid Biopsy” for physicians and researchers in related disciplines. The network, including third parties, also launches public relations campaigns on the subject of “Liquid Biopsy”, for example by sponsoring symposiums, presentations and press releases.

About SOPHiA GENETICS 

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact: 
Kelly Katapodis
media@sophiagenetics.com